{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T04:49:23Z","timestamp":1761540563175},"reference-count":39,"publisher":"Microbiology Society","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2004,11,1]]},"abstract":"<jats:p>Few data exist on the distribution of <jats:italic>Streptococcus pneumoniae<\/jats:italic> serotypes in many countries and in non-invasive disease overall. Here, data are presented from 772 paediatric isolates from children with community-acquired respiratory tract infections isolated from the PROTEKT global surveillance study during 1999\u20132000. Overall, 60.0 % of isolates were covered by the 7-valent pneumococcal vaccine formulation (PCV7), with greater coverage in the USA compared with Europe (69.6 vs 55.5 %, <jats:italic>P<\/jats:italic> = 0.014). Geographically dispersed clones of serogroups 3, 11 and 15 accounted for most of the isolates outside PCV7 coverage. Overall, macrolide, penicillin and cotrimoxazole non-susceptibility rates were high; however, all isolates were susceptible to telithromycin. Although only 7.4 % of isolates were resistant to amoxycillin\/clavulanate, a higher prevalence of resistance was found in isolates from the USA and South Korea. This study shows the feasibility and importance of serotyping antibiotic surveillance study isolates and the potential of telithromycin as an important option for empiric therapy.<\/jats:p>","DOI":"10.1099\/jmm.0.45647-0","type":"journal-article","created":{"date-parts":[[2004,10,20]],"date-time":"2004-10-20T23:09:52Z","timestamp":1098313792000},"page":"1109-1117","source":"Crossref","is-referenced-by-count":18,"title":["Global distribution of Streptococcus pneumoniae serotypes isolated from paediatric patients during 1999\u20132000 and the in vitro efficacy of telithromycin and comparators"],"prefix":"10.1099","volume":"53","author":[{"given":"D J","family":"Farrell","sequence":"first","affiliation":[{"name":"Medical and Molecular Microbiology, GR Micro Limited, 7\u20139 William Road, London NW1 3ER, UK 2Carolinas Medical Center, Charlotte, NC, USA 3Institute of Medical Microbiology, National Reference Center for Streptococci, Aachen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S G","family":"Jenkins","sequence":"additional","affiliation":[{"name":"Medical and Molecular Microbiology, GR Micro Limited, 7\u20139 William Road, London NW1 3ER, UK 2Carolinas Medical Center, Charlotte, NC, USA 3Institute of Medical Microbiology, National Reference Center for Streptococci, Aachen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R R","family":"Reinert","sequence":"additional","affiliation":[{"name":"Medical and Molecular Microbiology, GR Micro Limited, 7\u20139 William Road, London NW1 3ER, UK 2Carolinas Medical Center, Charlotte, NC, USA 3Institute of Medical Microbiology, National Reference Center for Streptococci, Aachen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"345","reference":[{"key":"H1-10","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1097\/00006454-200209000-00005","article-title":"& 8 other authors","volume":"21","author":"Black","year":"2002","journal-title":"Pediatr Infect Dis J"},{"key":"H2-10","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1046\/j.1469-0691.2003.00597.x","article-title":"& 13 other authors","volume":"9","author":"Bozdogan","year":"2003","journal-title":"Clin Microbiol Infect"},{"key":"H3-10","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1128\/AAC.44.2.414-417.2000","article-title":"In vitro development of resistance to telithromycin (HMR 3647), four macrolides, clindamycin, and pristinamycin in Streptococcus pneumoniae","volume":"44","author":"Davies","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"H4-10","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1367\/1539-4409(2001)001<0302:PECRTT>2.0.CO;2","article-title":"Physicians\u2019 early challenges related to the pneumococcal conjugate vaccine","volume":"1","author":"Davis","year":"2001","journal-title":"Ambul Pediatr"},{"key":"H5-10","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1542\/peds.112.3.521","article-title":"Influence of insurance status and vaccine cost on physicians\u2019 administration of pneumococcal conjugate vaccine","volume":"112","author":"Davis","year":"2003","journal-title":"Pediatrics"},{"key":"H6-10","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1046\/j.1469-0691.2001.0070s3024.x","article-title":"Pharmacodynamic and pharmacokinetic considerations in antimicrobial selection: focus on telithromycin","volume":"7 (Suppl. 3)","author":"Drusano","year":"2001","journal-title":"Clin Microbiol Infect"},{"key":"H7-10","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1093\/jac\/46.5.741","article-title":"Pharmacokinetics and comparative effects of telithromycin (HMR 3647) and clarithromycin on the oropharyngeal and intestinal microflora","volume":"46","author":"Edlund","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"H8-10","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1099\/00221287-144-11-3049","article-title":"A multilocus sequence typing scheme for Streptococcus pneumoniae : identification of clones associated with serious invasive disease","volume":"144","author":"Enright","year":"1998","journal-title":"Microbiology"},{"key":"H9-10","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1093\/jac\/48.4.541","article-title":"Detection of macrolide resistance mechanisms in Streptococcus pneumoniae and Streptococcus pyogenes using a multiplex rapid cycle PCR with microwell-format probe hybridization","volume":"48","author":"Farrell","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"H10-10","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/jac\/dkf806","article-title":"Molecular characterization of macrolide resistance mechanisms among Streptococcus pneumoniae and Streptococcus pyogenes isolated from the PROTEKT 1999-2000 study","volume":"50 (Suppl. S1)","author":"Farrell","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"H11-10","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1128\/AAC.47.6.1777-1783.2003","article-title":"Macrolide resistance by ribosomal mutation in clinical isolates of Streptococcus pneumoniae from the PROTEKT 1999-2000 study","volume":"47","author":"Farrell","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"H12-10","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1128\/JCM.42.2.764-768.2004","article-title":"Molecular epidemiology of multiresistant Streptococcus pneumoniae with both erm (B)- and mef (A)-mediated macrolide resistance","volume":"42","author":"Farrell","year":"2004","journal-title":"J Clin Microbiol"},{"key":"H13-10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/dkf807","article-title":"The need for antimicrobial resistance surveillance","volume":"50","author":"Felmingham","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"H14-10","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/jac\/45.2.191","article-title":"The Alexander Project 1996-1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections","volume":"45","author":"Felmingham","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"H15-10","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1179\/joc.1999.11.Supplement-2.5","article-title":"Trends in the antimicrobial susceptibility of bacterial respiratory tract pathogens \u2013 findings of the Alexander Project 1992-1996","volume":"11 (Suppl. 1)","author":"Felmingham","year":"1999","journal-title":"J Chemother"},{"key":"H16-10","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/jac\/dkf808","article-title":"Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and comparative in vitro activity of the ketolide, telithromycin","volume":"50 (Suppl. S1)","author":"Felmingham","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"H17-10","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0924-8579(02)00130-9","article-title":"Outcome of treatment of respiratory tract infections due to Streptococcus pneumoniae , including drug-resistant strains, with pharmacokinetically enhanced amoxycillin\/clavulanate","volume":"20","author":"File","year":"2002","journal-title":"Int J Antimicrob Agents"},{"key":"H18-10","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/jac\/48.suppl_2.25","article-title":"Activity of telithromycin, a new ketolide antibacterial, against atypical and intracellular respiratory tract pathogens","volume":"48 (Suppl. T1)","author":"Hammerschlag","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"H19-10","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1086\/313608","article-title":"Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I","volume":"30","author":"Hausdorff","year":"2000a","journal-title":"Clin Infect Dis"},{"key":"H20-10","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1086\/313609","article-title":"The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use, part II","volume":"30","author":"Hausdorff","year":"2000b","journal-title":"Clin Infect Dis"},{"key":"H21-10","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1086\/320181","article-title":"Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae , Haemophilus influenzae , and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999","volume":"32 (Suppl. 2)","author":"Hoban","year":"2001","journal-title":"Clin Infect Dis"},{"key":"H22-10","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1056\/NEJMoa022678","article-title":"& 7 other authors","volume":"348","author":"Jackson","year":"2003","journal-title":"N Engl J Med"},{"key":"H23-10","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1086\/323027","article-title":"Pneumococcal conjugate vaccine serotypes of Streptococcus pneumoniae isolates and the antimicrobial susceptibility of such isolates in children with otitis media","volume":"33","author":"Joloba","year":"2001","journal-title":"Clin Infect Dis"},{"key":"H24-10","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1056\/NEJMoa035060","article-title":"A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection","volume":"349","author":"Klugman","year":"2003","journal-title":"N Engl J Med"},{"key":"H25-10","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1136\/adc.88.3.211","article-title":"Pneumococcal nasopharyngeal carriage in children following heptavalent pneumococcal conjugate vaccination in infancy","volume":"88","author":"Lakshman","year":"2003","journal-title":"Arch Dis Child"},{"key":"H26-10","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1086\/315009","article-title":"Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine","volume":"180","author":"Mbelle","year":"1999","journal-title":"J Infect Dis"},{"key":"H27-10","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1128\/AAC.47.4.1433-1435.2003","article-title":"Molecular characterization and antimicrobial susceptibility of fluoroquinolone-resistant or -susceptible Streptococcus pneumoniae from Hong Kong","volume":"47","author":"Morrissey","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"H28-10","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1086\/514093","article-title":"Identification of cross-reactive antibodies with low opsonophagocytic activity for Streptococcus pneumoniae","volume":"176","author":"Nahm","year":"1997","journal-title":"J Infect Dis"},{"key":"H29-10","volume-title":"Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically . Approved Standard","year":"2003"},{"key":"H30-10","volume-title":"Performance Standards Antimicrobial Susceptibility Testing . Twelfth Information Supplement. NCCLS document M100-S14","year":"2004"},{"key":"H31-10","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0140-6736(05)65585-7","article-title":"Carriage of pneumococci after pneumococcal vaccination","volume":"348","author":"Obaro","year":"1996","journal-title":"Lancet"},{"key":"H32-10","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1093\/jac\/45.4.457","article-title":"Resistance surveillance of Streptococcus pneumoniae , Haemophilus influenzae and Moraxella catarrhalis isolated in Asia and Europe, 1997-1998","volume":"45","author":"Sahm","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"H33-10","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3201\/eid0901.020172","article-title":"Dead bugs don't mutate: susceptibility issues in the emergence of bacterial resistance","volume":"9","author":"Stratton","year":"2003","journal-title":"Emerg Infect Dis"},{"key":"H34-10","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1086\/322984","article-title":"Cross-reactivity of antibodies to type 6B and 6A polysaccharides of Streptococcus pneumoniae , evoked by pneumococcal conjugate vaccines, in infants","volume":"184","author":"Vakevainen","year":"2001","journal-title":"J Infect Dis"},{"key":"H35-10","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1185\/030079902125001191","article-title":"Efficacy and safety of telithromycin in community-acquired pneumonia","volume":"18","author":"Van Rensburg","year":"2002","journal-title":"Curr Med Res Opin"},{"key":"H36-10","doi-asserted-by":"crossref","first-page":"S140","DOI":"10.1007\/s00431-002-1067-9","article-title":"Will the 7-valent pneumococcal vaccine have a similar impact on all invasive pneumococcal infections in children in Germany as in the Kaiser Permanente Trial?","volume":"161 (Suppl. 2)","author":"Von Kries","year":"2002","journal-title":"Eur J Pediatr"},{"key":"H37-10","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa022823","article-title":"& 10 other authors","volume":"348","author":"Whitney","year":"2003","journal-title":"N Engl J Med"},{"key":"H38-10","volume-title":"Programme for the Control of Acute Respiratory Infections. Antibiotics in the Treatment of Acute Respiratory Infections in Young Children","year":"1990"},{"key":"H39-10","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1086\/315096","article-title":"Immunity to cross-reactive serotypes induced by pneumococcal conjugate vaccines in infants","volume":"180","author":"Yu","year":"1999","journal-title":"J Infect Dis"}],"container-title":["Journal of Medical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.microbiologyresearch.org\/content\/journal\/jmm\/10.1099\/jmm.0.45647-0?crawler=true","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T04:25:56Z","timestamp":1600835156000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.microbiologyresearch.org\/content\/journal\/jmm\/10.1099\/jmm.0.45647-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,11,1]]},"references-count":39,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2004,11,1]]}},"URL":"https:\/\/doi.org\/10.1099\/jmm.0.45647-0","relation":{},"ISSN":["0022-2615","1473-5644"],"issn-type":[{"value":"0022-2615","type":"print"},{"value":"1473-5644","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,11,1]]}}}